In Saudi Arabia, with over 32 million people and a growing healthcare industry, Admedus is now approved to sell their CardioCel biomaterial for heart valve repair surgeries and expand their Middle East presence. Admedus now sells CardioCel in many countries around the world and includes 135 medical centres, but Saudi Arabia is an important market for them since cardiovascular disease is the main cause of death in the country. They partnered with Genpharm for this expansion which is already active in Saudi Arabia and they are focusing on pediatric cardiac care first. The expansion is projected to keep Admedus on track for their anticipated $21 million revenue for the year. Wayne Paterson, CEO, told Proactive Investors, “This is the most significant approval for Admedus and our partners Genpharm in this key strategic region.”
Latest article
Meatable hosts distinguished guests for EU’s first cultivated meat tasting
In the Netherlands, Meatable has hosted the European Union’s first cultivated meat tasting. Michelin-starred chef Ron Blaauw; Constantijn van Oranje, Prince of the Netherlands...
Cool as a cucumber (coating): Sweden’s Saveggy raises $2.1 million for edible produce preserver
In Sweden, foodtech startup Saveggy has raised €1.76 (US$2.1 million) to scale up an edible cucumber coating made from a proprietary formula of canola...
Designer develops chitin-based seed pods
In New York, designer Mara Zimmerman has developed SEAD, a seed delivery and cultivation material made from discarded seafood cells.
Specifically, Zimmerman uses chitin from...